ALISO VIEJO, Calif., June 1 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the company is scheduled to make investor presentations at three investor conferences in the month of June.
- Jefferies 2010 Global Life Sciences Conference at 1:00 p.m. EDT on Tuesday, June 8 in New York City. The conference will be held June 8-11.
- Morgan Joseph 2010 Investor Conference at 4:00 p.m. EDT on Wednesday, June 9 in New York City. The conference will be held June 9 at the Millennium Broadway Hotel.
- ThinkEquity Mid-Year Check-Up on Healthcare Conference at 1:30 p.m. EDT on Wednesday, June 16 in New York City. The conference will be held June 16 at the Princeton Club.
A live webcast of each presentation will be available via a link provided at http://www.clarientinc.com/investor. Archived replays of each presentation will also be available for a period of 90 days from the date of each presentation at http://www.clarientinc.com/investor.
Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services. Clarient's customers are connected to its Internet-based portal, PATHSITE®, that delivers high resolution images and critical interpretive reports based on our diagnostic testing. Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma. www.clarientinc.com
Allen & Caron, Inc.
SOURCE Clarient, Inc.